Antonio Galeone

[David M. Sabatini @DMSabatini]

For a variety of reasons, we’ve been quantitating many western blots & radioactive protein gels so made this app for doing so as unhappy with what is available. Can quickly quantitate gels/blots & make simple graphs from the data. Instruction tab in app.
https://t.co/fdx1stYA8f

[bioRxiv Genetics @biorxiv_genetic]

Mesodermal-specific MECP2 expression in Drosophila induces visceral and skeletal muscle defects rescued by butyrate supplementation https://t.co/uqph3PpUxV #biorxiv_genetic

[biorxiv_devbio @biorxiv_devbio]

TUSC3 serves as a rate-limiting gatekeeper of a glycan-mediated ER Triage Checkpoint for BMP4/Dpp https://t.co/T1mRkmubgF #biorxiv_devbio

[Antonio Galeone @Galeone81]

We are hiring a PostDoc (Genetics, Molecular biology, Rare diseases) The initial appointment is 1 year with a competitive salary.
https://t.co/NxLOVYIi9n
Please RT.

CNR - Istituto di Nanotecnologia
#MSCA
#nextgenerationEU
#CIPO
#RareDiseases
#MUR
#youngresearchers

[Miriam Merenciano @mirimerenciano]

Are you planning to perform CRISPR/Cas9 to delete TEs in Drosophila? 🧬✂️🧬Check out our (@GonzalezLab_BCN) protocol in @STARProtocols 👇
https://t.co/Xg4xsvkhLt

[Feng Zhang @zhangf]

Since the discovery of CRISPR-Cas systems, people have wondered if a similar type of system exists in eukaryotes. Today, we report in @Nature the characterization of Fanzor, a eukaryotic RNA-guided system that can be reprogrammed for human genome editing. https://t.co/aKLMMEBRkk

[Thomas Tueting @ThomasTueting]

Read our latest work on the power of CD4 T cells in cancer immunity:
https://t.co/A6oqVvnxO1

[Molecular Therapy Family of Journals @MolTherapy]

Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender enhanced protein expression in hepatic and extra-hepatic tissues #MTMCD https://t.co/hpELzl6TSx

[Francesco Bisconti @FrancescoBisco7]

I’m really happy to announce you that our collaboration with CNR of Catania has led to beautiful results published in the prestigious Nature sustainability. Look at our approach to reduce #PbLeakeage from #PerovskiteSolarCells.

[Nature Immunology @NatImmunol]

George Coukos and colleagues show that orthogonal cytokine engineering can reprogram CD8 T cells to escape exhaustion leading to tumor regression. Read it here: https://t.co/ToyXbu672u @CorriaJesus @CoukosGeorge

https://t.co/rsmwukHHuD

[Tigem Telethon @Tigem_Telethon]

#TigemDataClub
Today Chiara De Leonibus will introduce us her insights on Regulation of ER quality control by nutrient sensing machinery stimulus
More info about Carmine Settembre's Lab here:
https://t.co/6Rv9RaMBdD

[Ethan Perlstein 1-to-N @eperlste]

A pioneering 1-to-N study that began last November based on results from a fly drug multipurposing screen is expanding to two additional patients who just started treatment, and the first patient is now in a drug washout.

Welcome to the frontier of precision medicine.

[Gang Fang @gangfang_1]

Interested in DNA/RNA modification? Glad to share our paper @NatureRevGenet “Navigating pitfalls of mapping DNA & RNA modification”. VERY promising field, BUT we highlight *common yet not widely recognized pitfalls*. Congrats @kong_yimeng! High-level🧵1/11 https://t.co/6f2ddrDLz9

[jlenia Monfregola @jleniaMonfrego]

Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases | Nature Biotechnology https://t.co/uDCXY8qBj7

[Clement Chow @ClementYChow]

As @mattmight says, "science is medicine" for rare disease. It's pretty amazing that we can use fairly simple approaches (repurposing drug screens) in flies to bring potential life changing therapies to people living with rare disease. In this case, the experiment is the therapy.

[Grace Science @gracescience]

2 special milestones this week...Grace got to celebrate First Holy Communion & turned 13. Hard to believe she is a teenager. Doctors told us she wouldn't live past 5 when she was born. Thankful for these 2 incredible milestones. #NGLY1 #RareDisease #firstcommunion #Birthdaygirl

[eLife - the journal @eLife]

Today, we’re introducing a new model that eliminates accept/reject decisions.

By publishing every paper with eLife reviews as a Reviewed Preprint, we plan to restore autonomy to authors, ensuring that they will be judged by what, not where, they publish. https://t.co/OAsiOVFStI

[Grace Science @gracescience]

Excited @NobelPrize goes to friend, colleague, & grantee @CarolynBertozzi. She changed the #NGLY1 field that is poised to impact several diseases that touch millions of ppl (not just the #RareDisease we started w/). Love her rocking Grace Science "Cure All" shirt in @nytimes pic.

[Thomas Vaccari @vaccart]

We have a #postdoc position open in the lab! Check out the ad 👇👇 Please apply or share/retweet. #jobs #science

[Ashraf Saad, bridging Glycobiology and Oncology! @AsAshraf123321]

#glycotime
In this review, we discuss recent advances in cancer immunotherapies involving glycans and glycan-targeting technologies based on nanomaterial-assisted local delivery systems.
Amazing research article 👌👏🎊
https://t.co/zlIE5g7JPb